Canceled by the investigator. Observation on the efficacy of Olotadine Hydrochloride combined with ebastine in the treatment of chronic eczema And its effect on serum IgE and IL-6 levels

Observation on the efficacy of Olotadine Hydrochloride combined with ebastine in the treatment of chronic eczema And its effect on serum IgE and IL-6 levels

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070958

Enrollment

Unknown

Registered

2023-04-27

Start date

2021-07-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eczema

Interventions

treatment group:Olotadine Hydrochloride Tablets+Epistine Tablets

control group:Epistine Tablets

Health Group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ? Age: 18-60 years old; ? Sign an informed consent form to voluntarily join the study; ? Refer to the diagnostic criteria for eczema in "Chinese Clinical Dermatology" (published by Jiangsu Phoenix Science and Technology Press, edition: 2nd edition), edited by Zhao Bian in 2017.

Exclusion criteria

Exclusion criteria: ? Pregnant or lactating women; ? Allergic to the test drug or to the drug components; ? Have taken steroids within the past two weeks, and/or have used antihistamines or topical steroids within one week; ? Excluding those with severe primary diseases such as cardiovascular, brain, liver, kidney, and hematopoietic systems.

Design outcomes

Primary

Measure	Time frame
Eczema area and severity index score;IL-6;Serum IG-E;	—

Secondary

Measure	Time frame
Eosinophils;	—

Countries

china

Contacts

Public Contactze-chao ZHANG

Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine

edwardbangong@163.com+8617671793908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026